HOUSTON, July 6, 2026
Moleculin Biotech announced that Chairman and Chief Executive Officer Walter Klemp discussed encouraging preliminary results from the company’s pivotal Phase 2/3 MIRACLE trial during a Virtual Investor “What This Means” segment. The presentation focused on early unblinded efficacy findings from the first 45 patients enrolled in Part A of the study evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). The discussion reviewed early efficacy trends observed across both Annamycin treatment arms and outlined the potential commercial opportunity if the therapy ultimately receives regulatory approval.
Early MIRACLE Data Demonstrate Encouraging Clinical Activity
The MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) trial is a pivotal, adaptive, multicenter, randomized, double-blind, placebo-controlled Phase 2/3 study evaluating AnnAraC in patients with relapsed or refractory acute myeloid leukemia. According to the company, preliminary unblinded data from the first 45 enrolled patients demonstrated positive efficacy trends across both active treatment groups. While detailed efficacy metrics were not disclosed in the announcement, company leadership described the early findings as encouraging and supportive of continued development of Annamycin in this difficult-to-treat patient population.
Annamycin Designed to Address Limitations of Conventional Anthracyclines
Annamycin, also known as naxtarubicin, is a next-generation anthracycline engineered to overcome multidrug resistance mechanisms while avoiding the cardiotoxicity commonly associated with conventional anthracycline chemotherapy. The investigational therapy is being developed for patients with relapsed or refractory AML, where treatment options remain limited and outcomes are generally poor. Following encouraging results from the earlier Phase 1b/2 MB-106 study, Moleculin has stated that discussions with the U.S. Food and Drug Administration have helped establish a development pathway toward potential regulatory approval, although future regulatory review and additional clinical data remain necessary.
Advertisement
Moleculin Continues Advancing Oncology Pipeline
Beyond Annamycin, Moleculin is advancing a broader oncology and antiviral development pipeline. The company is developing WP1066, an investigational immune and transcription modulator targeting STAT3 and other oncogenic signaling pathways for brain tumors, pancreatic cancer, and additional malignancies. Its pipeline also includes WP1122, an investigational antimetabolite being explored for the treatment of certain cancers and pathogenic viral infections. The continued progress of the MIRACLE trial represents an important milestone in Moleculin’s strategy to develop innovative therapies for patients with high unmet medical needs in oncology.
Source:Moleculin Biotech press release
